
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023

Somatec Pharmaceuticals Ltd. · Tablet
/ Piece
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
Flavoxate is indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis and urethrocystitis.
Flavoxate acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, urge incontinence episodes, urge severity and improving retention, facilitating increased volume per void.
The usual dosage of Flavoxate Hydrochloride for patients older than 12 years of age is 100-200 mg 3 or 4 times daily. Dosage may be reduced as symptoms improve. In patients with infections, treatment is usually continued for as long as antibacterial or antiinfective medications are administered. In patients with chronic bladder symptoms, maintenance therapy for prolong periods may be required for optimum results.
Side effects of Flavoxate Hydrochloride include nausea and vomiting, dry mouth and throat, nervousness, vertigo, headache, drowsiness, blurred vision, increased ocular tension, disturbance in ocular accommodation, urticaria and other dermatoses, mental confusion, dysuria, tachycardia and palpitation, hyperpyrexia, and eosinophilia. Rarely, abdominal pain and difficulty in concentration may occur. Constipation has been reported in patients receiving 800 mg to 1.2 g of Flavoxate Hydrochloride daily.
There are no well-controlled studies using Flavoxate Hydrochloride in pregnant women and therefore the drug should be used during pregnancy only when clearly needed. Since it is not known whether Flavoxate Hydrochloride is distributed into milk, the drug should be used with caution in nursing women.
Because of possible drowsiness, vertigo, and ocular disturbances, Flavoxate Hydrochloride should be administered with caution to patients performing hazardous tasks requiring mental alertness or physical coordination. Flavoxate Hydrochloride should also be administered with caution to patients with suspected glaucoma.
BPH/ Urinary retention/ Urinary incontinence
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.